Use of akkermansia for treating metabolic disorders

Abstract

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

1 . A method for treating cancer in a subject in need thereof, the method comprising administering  Akkermansia muciniphila  or fragments thereof to the subject. 
     
     
         2 - 5 . (canceled) 
     
     
         6 . The method of  claim 1 , wherein viable cells of  Akkermansia muciniphila  are administered to the subject in need thereof. 
     
     
         7 . The method of  claim 1 , wherein the  Akkermansia muciniphila  is orally administered. 
     
     
         8 . The method of  claim 1 , wherein an amount of  Akkermansia muciniphila  ranging from about 1.10 4  to about 1.10 12  cfu, from about 1.10 5  to about 1.10 11  cfu, or from about 1.10 6  to about 1.10 10  cfu is administered to the subject. 
     
     
         9 . The method of  claim 1 , wherein the  Akkermansia muciniphila  is administered at least three times a week. 
     
     
         10 . The method of  claim 1 , wherein the  Akkermansia muciniphila  is co-administered with another probiotic strain and/or with one or more prebiotics. 
     
     
         11 . The method of  claim 1 , wherein the  Akkermansia muciniphila  is administered as a composition in association with an excipient. 
     
     
         12 . The method of  claim 11 , wherein said composition is a nutritional composition. 
     
     
         13 . The method of  claim 11 , wherein said composition is orally administered. 
     
     
         14 . The method of  claim 1 , wherein the  Akkermansia muciniphila  is administered as a pharmaceutical composition comprising a pharmaceutically acceptable vehicle. 
     
     
         15 - 17 . (canceled) 
     
     
         18 . A method for treating cancer in a subject in need thereof, the method comprising orally administering a composition comprising a therapeutically effective amount of bacteria comprising substantially purified  Akkermansia  to the subject, wherein the substantially purified  Akkermansia  comprises at least 50% of a strain of  Akkermansia.    
     
     
         19 . The method of  claim 18 , wherein the substantially purified  Akkermansia  is co-administered with another probiotic strain and/or with one or more prebiotics. 
     
     
         20 . The method of  claim 18 , wherein the bacteria comprise a mixture of bacterial strains in which at least 50% of the bacterial strains in the composition are Verrucomicrobia, Bacteroidetes, Firmicutes, or Proteobacteria. 
     
     
         21 . The method of  claim 19 , wherein the one or more prebiotics comprises a fructooligosaccharide, a glucooligosaccharide, a xylooligosaccharide, a galactooligosaccharide, an arabinoxylan, an arabinogalactan, a galactomannan, a polydextrose, an oligofructose, an inulin, a derivative thereof, or a combination thereof. 
     
     
         22 . The method of  claim 18 , wherein the composition further comprises a coating, wherein the coating does not begin to degrade until after it exits a stomach of the subject. 
     
     
         23 . The method of  claim 18 , wherein the relative abundance of the  Akkermansia  strain in the subject is increased by at least 5%. 
     
     
         24 . The method of  claim 18 , wherein the  Akkermansia  is lyophilized. 
     
     
         25 . The method of  claim 18 , wherein the composition is administered in one or more doses per day. 
     
     
         26 . The method of  claim 18 , wherein the composition is administered at a dose of from about 0.001 to about 100 mg/kg body weight of the subject, about 0.01 to about 50 mg/kg body weight of the subject, or about 0.05 to about 10 mg/kg body weight of the subject. 
     
     
         27 . A method for treating cancer in a subject in need thereof, the method comprising administering a pharmaceutical composition comprising:
 a therapeutically effective amount of a substantially purified  Akkermansia , wherein the substantially purified  Akkermansia  comprises at least 50% of a strain of  Akkermansia;      a prebiotic; and   a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is formulated for oral delivery and encapsulated by a coating, and wherein the coating does not fully degrade until after it exits the stomach of a subject.